Compounds > razaxaban
Page last updated: 2024-09-05

razaxaban and isoxazoles

razaxaban has been researched along with isoxazoles in 9 studies

Compound Research Comparison

Studies
(razaxaban)		Trials
(razaxaban)		Recent Studies (post-2010)
(razaxaban)		Studies
(isoxazoles)		Trials
(isoxazoles)		Recent Studies (post-2010) (isoxazoles)
20028,6339003,337

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alexander, RS; Bai, S; Clark, CG; Ellis, CD; Han, Q; He, MY; Knabb, RM; Lam, PY; Li, R; Luettgen, JM; Pinto, DJ; Quan, ML; Sun, JH; Teleha, CA; Wexler, RR; Wong, PC1
Badawy, SI; Gray, DB; Hussain, MA; Schuster, AE; Sun, D; Zhao, F1
Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC1
Bonacorsi, SJ; Chen, SY; He, K; Knabb, RM; Lam, PY; Lecureux, L; Patrone, LM; Quan, M; Raghavan, N; Skiles, GL; Zhang, D; Zhang, H1
Badawy, SI; Friedman, EM; Hilden, LR; Pommier, CJ1
Alexander, RS; Amparo, E; Kish, K; Knabb, RM; Luettgen, JM; Morin, P; Pinto, DJ; Quan, ML; Rossi, KA; Sheriff, S; Smallwood, A; Wexler, RR; Woerner, FJ1
Barrett, YC; Frost, C; Shenker, A; Wang, Z1
Davis, B; Farndale, RW; Jarvis, GE; Koch, A; Pugh, N; Sakariassen, KS1
Badawy, SI; LaMarche, K; Narang, AS; Subramanian, G; Varia, SA1

Other Studies

9 other study(ies) available for razaxaban and isoxazoles

ArticleYear
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Administration, Oral; Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Imidazoles; Isoxazoles; Models, Molecular; Permeability; Protein Binding; Pyrazoles; Rabbits; Structure-Activity Relationship; Thrombosis

2005
Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Pharmaceutical research, 2006, Volume: 23, Issue:5

    Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Dogs; Drug Interactions; Excipients; Factor Xa Inhibitors; Famotidine; Gastric Acid; Gastrointestinal Agents; Gastrointestinal Tract; Histamine H2 Antagonists; Hydrogen-Ion Concentration; Intestinal Absorption; Isoxazoles; Pentagastrin; Povidone; Pyrazoles; Solubility; Tablets

2006
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
    Journal of thrombosis and thrombolysis, 2007, Volume: 24, Issue:1

    Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine

2007
Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:2

    Topics: Animals; Anticoagulants; Benzamidines; Bile; Biotransformation; Cells, Cultured; Dogs; Feces; Hepatocytes; Isoxazoles; Liver; Male; Oxidation-Reduction; Pyrazoles; Rats; Rats, Sprague-Dawley

2008
NIR chemical imaging to guide/support BMS-561389 tablet formulation development.
    International journal of pharmaceutics, 2008, Apr-02, Volume: 353, Issue:1-2

    Topics: Antithrombin III; Chemistry, Pharmaceutical; Excipients; Isoxazoles; Particle Size; Pyrazoles; Spectroscopy, Near-Infrared; Tablets; Tartrates; Technology, Pharmaceutical

2008
Phenyltriazolinones as potent factor Xa inhibitors.
    Bioorganic & medicinal chemistry letters, 2010, Feb-15, Volume: 20, Issue:4

    Topics: Anticoagulants; Crystallography, X-Ray; Drug Design; Factor Xa Inhibitors; Humans; Isoxazoles; Models, Molecular; Molecular Structure; Pyrazoles; Pyridones; Sulfones

2010
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism

2010
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
    Journal of thrombosis and thrombolysis, 2012, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Isoxazoles; Male; Middle Aged; Perfusion; Pyrazoles; Surface Properties; Thromboplastin; Thrombosis; Young Adult

2012
Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation.
    International journal of pharmaceutics, 2012, Dec-15, Volume: 439, Issue:1-2

    Topics: Alanine; Drug Compounding; Isoxazoles; Particle Size; Porosity; Powders; Pyrazoles; Quality Control; Solubility; Tablets; Technology, Pharmaceutical; Triazines; Water

2012